Literature DB >> 3035384

Stereoselective inhibition of calmodulin-dependent cAMP phosphodiesterase from bovine heart by (+)- and (-)-nimodipine.

C Schächtele, B Wagner, D Marmé.   

Abstract

The inhibitory effects of racemic (+/-)-nimodipine and of optically pure (+)- and (-)-nimodipine on the basal and calmodulin-dependent activity of a cAMP phosphodiesterase from bovine heart were investigated. The inhibition by (+/-)-nimodipine could not be overcome by an excess of calmodulin. However, increase of the cAMP concentration in the assay from 2 X 10(-4) mol/l to 2 X 10(-2) mol/l caused a shift of the IC50 for the inhibition by (+/-)-nimodipine from 2.8 X 10(-6) mol/l to 6 X 10(-5) mol/l. Dixon-plot analysis revealed an inhibitory constant of Ki = 2.3 mumol/l. Experiments with the two enantiomers showed that (+)-nimodipine is by about one order of magnitude more potent than (-)-nimodipine. This contrasts with the stereoselectivity of the Ca2+ channel inhibitory activity on isolated rings of the rabbit basilar artery where (-)-nimodipine is more effective than (+)-nimodipine in relaxing the smooth muscle contracted by K+-depolarisation. It is concluded that cAMP phosphodiesterase may be an intracellular target for nimodipine and its inhibition may contribute to the pharmacological activity of this 1,4-dihydropyridine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035384     DOI: 10.1007/BF00172808

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  16 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  Ca2+ antagonist receptor sites on human red blood cell membranes.

Authors:  J Striessnig; G Zernig; H Glossmann
Journal:  Eur J Pharmacol       Date:  1985-02-05       Impact factor: 4.432

3.  Antagonism of calmodulin and phosphodiesterase by nifedipine and related calcium entry blockers.

Authors:  A E Minocherhomjee; B D Roufogalis
Journal:  Cell Calcium       Date:  1984-02       Impact factor: 6.817

4.  Dihydropyridine Ca2+ entry blockers selectively inhibit peak I cAMP phosphodiesterase.

Authors:  J A Norman; J Ansell; M A Phillips
Journal:  Eur J Pharmacol       Date:  1983-09-16       Impact factor: 4.432

5.  Interaction of the antihypertensive drug felodipine with calmodulin.

Authors:  S L Bostróm; B Ljung; S Mårdh; S Forsen; E Thulin
Journal:  Nature       Date:  1981-08-20       Impact factor: 49.962

6.  The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle.

Authors:  R Towart; E Wehinger; H Meyer; S Kazda
Journal:  Arzneimittelforschung       Date:  1982

7.  Stimulation by nifedipine of calcium transport by cardiac sarcolemmal vesicles from spontaneously hypertensive rats.

Authors:  M David-Dufilho; M A Devynck; S Kazda; P Meyer
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

Review 8.  Sites of action of Ca2+ channel inhibitors.

Authors:  R A Janis; A Scriabine
Journal:  Biochem Pharmacol       Date:  1983-12-01       Impact factor: 5.858

9.  Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles.

Authors:  D C Pang; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

10.  Uptake of calcium antagonistic drugs into muscles as related to their lipid solubilities.

Authors:  D C Pang; N Sperelakis
Journal:  Biochem Pharmacol       Date:  1984-03-01       Impact factor: 5.858

View more
  6 in total

1.  Selective biotransformations. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1989-12       Impact factor: 2.926

2.  A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits.

Authors:  J Santafé; M J Martínez de Ibarreta; J Segarra; J Melena; M Garrido
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

3.  Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions.

Authors:  Alexandre E Medina
Journal:  Front Neurosci       Date:  2011-02-18       Impact factor: 4.677

4.  A novel 1,4-dihydropyridine-binding site on mitochondrial membranes from guinea-pig heart, liver and kidney.

Authors:  G Zernig; H Glossmann
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

5.  Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes.

Authors:  Jonas Jurevicius; V Arvydas Skeberdis; Rodolphe Fischmeister
Journal:  J Physiol       Date:  2003-06-18       Impact factor: 5.182

6.  Hydrophobic properties of novel dihydronaphthyridine calcium antagonists and biological activity in porcine isolated cardiac and vascular smooth muscle.

Authors:  G Werner; W Klaus; G Kojda; U Fricke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.